HAGH Knockout A-549 Polyclonal Cells constitute a CRISPR/Cas9-edited polyclonal knockout cell population derived from the A-549 human lung adenocarcinoma cell line, designed for targeted disruption of the HAGH gene encoding glyoxalase II. This polyclonal knockout product provides a genetically heterogeneous loss-of-function model, enabling researchers to investigate the functional consequences of impaired glyoxalase pathway activity in a disease-relevant epithelial context. The cells are produced through CRISPR/Cas9-mediated gene disruption, resulting in a mixed population with varied editing outcomes that collectively ablate HAGH protein expression. This format is well-suited for bulk functional studies, including metabolic profiling and stress response assays, where clonal uniformity is not required.
The host cell line, A-549, is a widely utilized adherent epithelial model originally isolated from a 58-year-old Caucasian male with lung adenocarcinoma. These cells retain characteristics of type II alveolar epithelial cells and are extensively employed in cancer biology, drug metabolism, and toxicology research. Their robust growth characteristics and well-documented signaling landscape make them an ideal platform for studying metabolic vulnerabilities in non-small cell lung carcinoma. The knockout model leverages this established background to dissect the role of methylglyoxal detoxification in tumor cell physiology.
At the molecular level, HAGH (glyoxalase II) catalyzes the hydrolysis of S-D-lactoylglutathione to D-lactate and glutathione, functioning downstream of GLO1 in the glyoxalase pathway. This zinc-dependent enzyme is critical for detoxifying the cytotoxic glycolytic byproduct methylglyoxal, thereby preventing the formation of advanced glycation end-products (AGEs). HAGH activity is regulated by upstream factors such as Nrf2, HIF1A, and intracellular glutathione levels, while its activity influences downstream targets including D-lactate and glutathione availability, reduced methylglyoxal-derived AGEs, and NF-??B activity. The enzyme interacts directly with GLO1 and glutathione, forming a coordinated detoxification axis that mitigates carbonyl stress. In the knockout background, accumulation of S-D-lactoylglutathione and methylglyoxal is anticipated to disrupt redox homeostasis and promote glycation damage.
In the A-549 lung carcinoma context, HAGH knockout is predicted to compromise methylglyoxal detoxification, leading to elevated glycating agents and oxidative stress that may affect proliferation, survival, and therapeutic resistance. This makes the model particularly relevant for investigating how glyoxalase pathway dysfunction contributes to lung cancer metabolism and the cellular response to chemotherapeutic agents. Moreover, since methylglyoxal toxicity is implicated in diabetic complications and neurodegenerative disorders, the knockout cells serve as a versatile platform for translational studies across multiple disease areas.
Typical research applications encompass cancer metabolism studies, methylglyoxal toxicity profiling, glycation stress modeling, drug resistance investigations, and antioxidant defense characterization. Representative assays compatible with this model include western blotting and RT-qPCR for HAGH expression; glyoxalase II enzyme activity assays; methylglyoxal quantification by LC-MS; glutathione and D-lactate measurements; ROS detection; apoptosis assays using Annexin V; cell viability assessments via MTT; wound healing migration assays; and glycation adduct detection by ELISA or immunofluorescence. For further details on validation data and customization options, please contact Ascent Research.
